Thursday, January 05, 2023 2:19:39 PM
the Opioid Studies For Biel Have Been Posts Dozens Of Times.
And then tell Kelly to post them on the clinical evidence page of her website, because they're all conspicuous in their absence.
PLEASE don't paste any powerpoint slides or bar graphs or old quotes from Andy. CITE THE JOURNAL ARTICLE.
And don't cite any of Ilfeld's case studies. BIEL needs a clinical trial, not a Case Study.
And don't cite Ilfeld's current active ActiPatch Pilot study because (a) it's just a PILOT STUDY and (b) There aren't any endpoints, primary or secondary, regarding opioid use. The Primary endpoints are all about VAS scores (Likert scale), and only one secondary endpoint (#11, see link below) is about analgesics -- ALL analgesics, not just opioids.
https://clinicaltrials.gov/ct2/show/NCT05392803?cond=Phantom+Pain&locn=San+Diego&draw=2&rank=5
Ilfeld appears to be planning some opioid use endpoints in future trials. He hasn't started any of those yet.
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
